GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Xinhua Pharmaceutical Co Ltd (HKSE:00719) » Definitions » Goodwill-to-Asset

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Goodwill-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Shandong Xinhua Pharmaceutical Co Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Shandong Xinhua Pharmaceutical Co's Goodwill for the quarter that ended in Mar. 2024 was HK$0 Mil. Shandong Xinhua Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2024 was HK$9,199 Mil. Therefore, Shandong Xinhua Pharmaceutical Co's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 was 0.00.


Shandong Xinhua Pharmaceutical Co Goodwill-to-Asset Historical Data

The historical data trend for Shandong Xinhua Pharmaceutical Co's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Xinhua Pharmaceutical Co Goodwill-to-Asset Chart

Shandong Xinhua Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Shandong Xinhua Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Shandong Xinhua Pharmaceutical Co's Goodwill-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Xinhua Pharmaceutical Co's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Xinhua Pharmaceutical Co's Goodwill-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Xinhua Pharmaceutical Co's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Shandong Xinhua Pharmaceutical Co's Goodwill-to-Asset falls into.



Shandong Xinhua Pharmaceutical Co Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Shandong Xinhua Pharmaceutical Co's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/9063.233
=0.00

Shandong Xinhua Pharmaceutical Co's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Goodwill to Asset (Q: Mar. 2024 )=Goodwill/Total Assets
=0/9198.776
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Xinhua Pharmaceutical Co  (HKSE:00719) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Shandong Xinhua Pharmaceutical Co Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Shandong Xinhua Pharmaceutical Co's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Xinhua Pharmaceutical Co (HKSE:00719) Business Description

Traded in Other Exchanges
Address
No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo City, Shandong, CHN, 255086
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates the business through the following segments: Chemical bulk drugs, Preparations, Chemical intermediates, and other products. The company provides chemical bulk drug products, including metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, and L-dopa, it also dispenses formulation products such as compound liquorice tablets and nimodipine tablets. Its products address disorders related to the central nervous system and the cerebrovascular system with the help of antipyretics and analgesics.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Headlines

No Headlines